Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting…
| Price | $3.02 |
|---|---|
| Market cap | $16.34M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| 52-week range | 2.99-5.53 |
| Beta | 0.77 |
Explore NEUP's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.